a genetically engineered anti-TNF compound (trade name Enbrel) consisting of receptors that bind TNF; it is injected twice a week in the treatment of rheumatoid arthritis

A biologic drug, for the treatment of psoriasis. Etanercept is a human protein that inhibits TNF, thereby reducing psoriasis symptoms.

Etanercept is a recombinant human soluble tumor necrosis factor-alpha (TNFα) receptor. It is a small protein, with a molecular weight of 75 k Da (p75), that binds to TNFα and decreases its role in inflammatory diseases such as rheumatoid arthritis, juvenile rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis. In the United States, it is co-marketed by Amgen and Wyeth under the trade name Enbrel®.